摘要 |
Methods and compositions for promoting nitric oxide (NO) and/or cGMP activity in a subject. A precursor for nitric oxide, such as arginine, is orally administered together with an agonist for NO, including thioamino acids, substituted mono or polyphenol antioxidants and plant extracts that promote endothelium-dependent relaxation, to synergistically enhance NO activity and thereby cGMP activity. cGMP activity is further enhanced by concomitant administration of phosphodiesterase inhibitor, including inhibitors specific to type V phosphodiesterase, such as sildenafil, and non-specific inhibitors, particularly xanthines, such as theobromine. The formulations are used in the treatment of NO and/or cGMP insufficiency, and particularly conditions involving the cardiovascular, pulmonary and reproductive systems, such as erectile dysfunction or deficiency in luetenizing hormone releasing hormone. |